Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat fibrotic lung conditions such as idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease, as well as certain cancers.

GNH USA supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib acts on multiple receptor tyrosine kinases involved in fibrotic and oncologic pathways, providing therapeutic benefit in several serious lung diseases. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary capacity and delays worsening. - Non‑small cell lung cancer: inhibits tumor growth when used in combination with standard chemotherapy.

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of queasiness, may affect appetite. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Vomiting: expulsion of stomach contents. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates potential hepatic injury. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: such as hypertension or arterial thromboembolism. - Severe infections: opportunistic infections in immunocompromised patients. - Gastrointestinal perforation: rare but life‑threatening condition. - Interstitial lung disease exacerbation: worsening of underlying lung disease.

Before initiating therapy with Nintedanib, clinicians should consider several safety measures. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Cardiovascular assessment: evaluate blood pressure and history of thrombotic disease. - Bleeding risk evaluation: review concomitant anticoagulant or antiplatelet use. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Hepatic impairment dose adjustment: consider reduced dosing in moderate liver dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential. - P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: monitor for electrolyte disturbances. - Antihypertensives: watch for additive blood pressure effects. - St. John's wort: possible reduction in drug levels. - Herbal supplements affecting liver enzymes: assess on a case‑by‑case basis.